Table 2.
Patients' characteristics along the study.
| BJI population | Baseline | End of treatment | Follow-up | Normal values |
|---|---|---|---|---|
| Feces weight (g) | 60.5 (n = 54) | 61.5 (n = 46) | 72 (n = 46) | 100–200 |
| MDRB fecal carriage (%) | 17.54 | 25.00 | 39.13 | NA |
| DNA extraction | 1.04 ± 0.14 | 0.69 ± 0.12 | 0.84 ± 0.14 | NA |
| Neopterina (pmol/g) | 97.7 | 494.7b | 285.4b | 55 |
| Calprotectina (μg/g) | 128.6 | 49.4b | 53.5b | <50 |
| Zonulina (ng/mL) | 85.2 | 128.1b | 131.0b | 61 ± 46 |
| IgAa (μg/g) | 2,187.6 | 2,235.5 | 2,204.7 | 2,000 |
| CRPc (mg/L) | 50.3 | 6 | 6.6 | <5 |
a
Quantification in fecal supernatants.
b
Significant p value <0.05, Wilcoxon test.
c
Blood quantification.
BJI, bone and joint infection; MDRB, multidrug-resistant bacteria; IgA, immunoglobulin A; CRP, C-reactive protein; NA, not applicable.